These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 28184982

  • 21. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C.
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [Abstract] [Full Text] [Related]

  • 22. Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
    Frustaci AM, Tedeschi A, Deodato M, Mazzucchelli M, Cairoli R, Montillo M.
    Future Oncol; 2018 Apr; 14(8):681-697. PubMed ID: 29243946
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Ibrutinib resistance in chronic lymphocytic leukemia.
    Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, Racchumi J, Xu G, Wu H, Ma J, Steggerda SM, Coleman M, Leslie C, Wang YL.
    N Engl J Med; 2014 Jun 12; 370(24):2352-4. PubMed ID: 24869597
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Ibrutinib in B lymphoid malignancies.
    Smith MR.
    Expert Opin Pharmacother; 2015 Jun 12; 16(12):1879-87. PubMed ID: 26165513
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. New approved indication for ibrutinib.
    Aschenbrenner DS.
    Am J Nurs; 2014 Jun 12; 114(6):21. PubMed ID: 24869579
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA.
    JAMA Oncol; 2015 Apr 12; 1(1):80-7. PubMed ID: 26182309
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J, Jimeno A.
    Drugs Today (Barc); 2014 Apr 12; 50(4):291-300. PubMed ID: 24918646
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A.
    Haematologica; 2015 Dec 12; 100(12):1495-507. PubMed ID: 26628631
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.